Preclinical News and Research

RSS

Olive oil type matters for cognition and gut health in older adults

Higher intake of virgin and total olive oil was associated with modest but significant improvements in cognitive performance over two years in older adults with metabolic syndrome. These associations were partly linked to gut microbiota composition, with specific taxa such as Adlercreutzia contributing a small mediating effect.

26 Jan 2026

Tiny plastic particles may interfere with brain processes implicated in Parkinson’s disease

Micro- and nanoplastics are increasingly detected in human tissues, including the brain, and experimental evidence suggests they can interact with biological pathways central to Parkinson’s disease pathology. This review synthesises mechanistic data indicating that plastic particles may influence protein aggregation, neuroinflammation, mitochondrial dysfunction, and the gut–brain axis, while emphasising the need for prospective human studies.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Trojan horse immunotherapy opens tumors to immune system attack

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them.

22 Jan 2026

Menopausal hormone therapy linked to greater weight loss with tirzepatide

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity.

22 Jan 2026

Discovery explains why people with IBD have higher risk of colorectal cancer

A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone marrow—may help explain why people with inflammatory bowel disease (IBD) have a higher risk of colorectal cancer, according to a preclinical study by Weill Cornell Medicine investigators.

22 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

Study identifies a powerful strategy to overcome drug resistance in breast cancer

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.

22 Jan 2026

Chemotherapy-induced gut changes trigger anti-metastatic immune response

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to the gut.

22 Jan 2026

High-dose inhaled nitric oxide could fight multidrug-resistant infections

Overuse of antibiotics has accelerated the development of bacterial resistance to conventional drugs, a global health crisis projected to result in more than 10 million deaths annually by 2050.

21 Jan 2026

UC Irvine wins ARPA-H award to advance lymphatic disease diagnosis

The University of California, Irvine has received its first award from the Advanced Research Projects Agency for Health, launching a major effort to improve how doctors detect and treat diseases of the lymphatic system.

21 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

Evidence shows no autism risk from paracetamol in pregnancy

Evidence from a comprehensive review shows no link between paracetamol in pregnancy and neurodevelopmental issues, supporting its safe use for pain management.

21 Jan 2026

Rice’s SynthX Center leads interdisciplinary effort to tackle rare lymphatic disorders

Rice University's SynthX Center, directed by Han Xiao, has received an up to five-year, $18 million award from the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics and pHenotyping Technologies (LIGHT) program to develop innovative solutions for lymphatic diseases.

20 Jan 2026